AKAnna Keramida

Anna Keramida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Keramida has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Brivaracetam in Off-Label Use and Special Populations: A Narrative Review of Current Evidence

    by Anna Keramida, Katerina Poprelka, Meropi Mousdi, Vasiliki Kotsali-Peteinelli, Maria-Ioanna Stefanou, Anastasios Bonakis, Georgios Tsivgoulis, Andreas Kyrozis, Panagiota-Eleni Tsalouchidou

    Background: Brivaracetam (BRV) is a synaptic vesicle protein 2A (SV2A) ligand approved for the treatment of focal-onset seizures. Its clinical use has increasingly expanded beyond approved indications and into understudied populations. Objective: We aim to review BRV use beyond approved indications and in special populations. Methods: MEDLINE, Embase, and Scopus were searched from inception to 30 April 2026. Eligible clinical studies were selected using prespecified criteria and synthesized narratively. Off-label status was determined separately under FDA and EMA labelling. Results: The evidence consisted predominantly of observational studies, real-world cohorts, case series, and subgroup analyses of randomised trials. In genetic generalized epilepsies (GGE), BRV was associated with seizure reduction in several cohorts, whereas findings in developmental and epileptic encephalopathies (DEEs) were more heterogeneous. Real-world studies demonstrated the feasibility of BRV monotherapy, particularly following transition from levetiracetam. In status epilepticus (SE), intravenous BRV has been associated with SE cessation, although its independent contribution, optimal dose and timing, and role in treatment algorithms remain uncertain. Pregnancy and breastfeeding reports identified no clear safety signal, although exposure and long-term outcome data were scarce. Neonatal evidence was restricted largely to pharmacokinetic and short-term tolerability findings. Observational data indicated that psychiatric or behavioural adverse effects did not recur in some patients switched from levetiracetam; evidence in psychotic disorders remained particularly limited. Conclusions: BRV may be useful in selected off-label settings and special populations. However, evidence remains limited and largely observational, so treatment decisions should be individualized. Prospective controlled studies and dedicated registries are needed.

  • Open Access

    Psychological resilience as a key pathway between depression and executive functioning in epilepsy

    by Katerina Poprelka, Panagiota-Eleni Tsalouchidou, Konstantina Stavrogianni, Maria Stefanatou, Anastasia Verentzioti, Anna Keramida, Vasiliki Kotsali-Peteinelli, Athanasia Alexoudi, Anastasios Bonakis, Lampis C. Stavrinou, et al.

  • Open Access

    Resilience as a mediating mechanism between psychological distress and quality of life in epilepsy

    by Katerina Poprelka, Konstantina Stavrogianni, Panagiota-Eleni Tsalouchidou, Maria Stefanatou, Anna Keramida, Anastasia Verentzioti, Vasiliki Kotsali-Peteinelli, Athanasia Alexoudi, Anastasios Bonakis, Lampis C. Stavrinou, et al.

  • Alexithymia and its relationship with cognition and psychological outcomes in patients with drug-resistant epilepsy

    by Katerina Poprelka, Panagiota-Eleni Tsalouchidou, Konstantina Stavrogianni, Anna Keramida, Vasiliki Kotsali-Peteinelli, Maria Stefanatou, Anastasia Verentzioti, Athanasia Alexoudi, Anastasios Bonakis, Stylianos Gatzonis

  • Open Access

    Risk of Diabetes Mellitus in the Myasthenia Gravis: A Systematic Review and Meta-Analysis

    by Vasileios Giannopapas, Maria-Ioanna Stefanou, Vasiliki Zouvelou, Georgia Papagiannopoulou, Vassiliki Smyrni, Maria Kosmidou, Dimitrios K. Kitsos, Anna Keramida, Stavroula Salakou, Georgios Tsivgoulis, et al.

    Background/Objectives: Myasthenia gravis (MG) comprises an autoimmune disorder marked by muscle weakness and fatigue. MG frequently coexists with other autoimmune conditions, such as diabetes mellitus, which may exacerbate the clinical burden of MG and adversely impact overall quality of life. Methods: This systematic review and meta-analysis aimed to assess the prevalence of diabetes in patients with MG. Following PRISMA guidelines, a comprehensive search was conducted in the MEDLINE PubMed, Scopus, and Google Scholar databases. Results: A total of 11 studies comprising 16,825 patients were included. The pooled prevalence of diabetes among MG patients was 15.6% (95% CI [8.4%, 24.7%]; I2 = 99%, p < 0.001). Compared to healthy controls, MG patients had a 1.24-fold increased risk of developing diabetes (95% CI [1.01–1.54], p < 0.001). Meta-regression showed no association between age and diabetes prevalence, although potential publication bias was noted (Egger’s test, p = 0.72). Conclusions: This meta-analysis reveals a higher prevalence of diabetes among MG patients, with an elevated risk compared to healthy individuals. These findings suggest that the association between MG and diabetes may be mediated by corticosteroid use, genetic factors, and reduced physical activity. The main limitations of this study are the lack of reported data regarding the type of diabetes and patients’ demographic and disease characteristics (MG classification severity and duration and type of treatment). Further studies are needed to investigate the underlying causal mechanisms and to elucidate the relationship between MG and diabetes subtypes.


  • Open Access

    Cenobamate in developmental and epileptic encephalopathies and generalized epilepsies: A case report on epilepsy with myoclonic-atonic seizures and systematic review of current evidence

    by Zafeirenia Vlakou, Anna Keramida, Vasiliki Kotsali-Peteinelli, Alexandros Matsingos, Maria Konstantinidi, Maria Chondrogianni, Georgios Tsivgoulis, Anastasios Bonakis, Panagiota-Eleni Tsalouchidou


  • A potentially fatal meningoencephalitis following intramuscular anti-inflammatory injection

    by Anna Keramida, Aikaterini Theodorou, Foteini Merkouri, Sotirios Tsiodras, Georgios Tsivgoulis

  • Open Access

    Paraneoplastic Neurological Syndromes as Initial Presentation of Tumors: An Eight-Year Single-Center Experience

    by Konstantinos Melanis, Maria-Ioanna Stefanou, Dimitrios K. Kitsos, Athanasia Athanasaki, Aikaterini Theodorou, Eleftheria Koropouli, Anna Keramida, Evangelia Makrina Dimitriadou, Dimitrios Tzanetakos, Elizabeth Andreadou, et al.

    Background: Paraneoplastic Neurological Syndromes (PNS) comprise a diverse group of disorders propagated by immune-mediated effects of malignant tumors on neural tissue. Methods: A single-center longitudinal study was performed including consecutive adult patients treated at a tertiary academic hospital between 2015 and 2023 and diagnosed with PNS. PNS were ascertained using the 2004 and the revised 2021 PNS-Care diagnostic criteria. Results: Thirteen patients who fulfilled the 2004 definite PNS criteria were included. PNS comprise diverse neurological syndromes, with neuromuscular junction disorders (54%) and limbic encephalitis (31%) being predominant. PNS-related antibodies were detected in 85% of cases, including anti-AChR (n = 4), anti-P/Q-VGCC (n = 3), anti-Hu (n = 3), anti-Yo (n = 1), anti-Ma (n = 1), anti-titin (n = 1), anti-IgLON5 (n = 1), and anti-GAD65 (n = 1). Thymoma (31%), small-cell lung cancer (23%), and papillary thyroid carcinoma (18%) were the most frequent tumors. Imaging abnormalities were evident in 33% of cases. Early immunotherapy within 4-weeks from symptom onset was associated with favorable outcomes. At a mean follow-up of 2 ± 1 years, two patients with anti-Hu and anti-Yo antibodies died (18%). Four and three patients fulfilled the 2021 PNS-Care diagnostic criteria for definite and probable PNS, respectively. Conclusions: This study highlights the clinical heterogeneity of PNS, emphasizing the need for early suspicion and prompt treatment initiation for optimal outcomes.


  • Reproductive health in patients with epilepsy

    by Sofia Markoula, Eleftheria Siarava, Anna Keramida, Dimitrios Chatzistefanidis, Athanassios Zikopoulos, Athanassios P. Kyritsis, Ioannis Georgiou